Navigation Links
Phase III pivotal results presented of VYVANSE to treat ADHD in adults
Date:5/8/2008

WASHINGTON, May 8 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today presented the results of a phase III pivotal study in which VYVANSE demonstrated significant improvements in Attention Deficit Hyperactivity Disorder (ADHD) symptoms in adults and met all safety and efficacy endpoints.

"Adults with ADHD often find it challenging to focus and organize during the day. The disorder may impact many aspects of their lives from career to family and personal commitments," said Lenard A. Adler, M.D., lead researcher in this study and director of the Adult ADHD program at the NYU Langone Medical Center, associate professor of psychiatry, neurology and child and adolescent psychiatry at the New York University School of Medicine, as well as author of Scattered Minds: Help and Hope for Adults with ADHD (G. P. Putnam's Sons 2006). "This study demonstrated that VYVANSE significantly improved ADHD symptoms in adults, including inattention, such as the ability to focus, organize and complete tasks, which are essential during an adult day, as well as hyperactivity, such as restlessness, and impulsivity."

This double-blind, placebo-controlled, four-week, forced-dose study in 414 adults aged 18 to 55 years showed that treatment with VYVANSE at all doses studied (30 mg, 50 mg, 70 mg) provided a significant reduction in ADHD Rating Scale (ADHD-RS-IV) scores within one week that were observed throughout the full treatment period. At endpoint, VYVANSE demonstrated a significant improvement in ADHD symptoms, based on a 43 percent reduction in ADHD-RS scores. This is the largest placebo-controlled stimulant trial of ADHD in adults conducted to date.

Additional Study Findings Investigators also measured the efficacy of VYVANSE with the Clinical Global Impressions-Improvement (CGI-I) scale and found that the percentage of subjects taking VYVANSE rated "much improved" or "very much improved"
'/>"/>

Contact: Lucia Lodato
lucia.lodato@porternovelli.com
917-617-3058
Porter Novelli
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Preliminary Results from Phase 2 Genzyme Study Highlight Potential of Novel Oral Compound for Gaucher Disease
2. NicOx Announces U.S. Phase 2a Results for PF-03187207 and Gives an Update on Continuing NO-prostaglandin Program
3. Phase 3 data Re: Anti-RSV antibody to be presented at Pediatric Academic Societies Annual Meeting
4. Wal-Mart Launches Phase Three of $4 Prescription Program
5. Sanofi-aventis: Encouraging First-Quarter 2008 Results Further Positive Phase III Results for Eplivanserin
6. Antipodean Pharmaceuticals Announces Results of Phase 2 Study of Lead Compound MitoQ(R)
7. Arpida Provides Comprhensive Overview of Pivotal Phase III Trial Data
8. QLT initiates phase II study of punctal plug drug delivery system for glaucoma & ocular hypertension
9. Cystic Fibrosis Foundation announces positive early results for phase 2 clinical trial of VX-770
10. Many Phase 3 Cancer Drug Trials Yield Effective Medicines
11. Cancer treatments in phase 3 trials successful up to half of the time
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... CA (PRWEB) October 20, 2014 JZ ... expertise, nutritional coaching, corporate wellness programming, authorship, international lecturing ... is excited to announce the release of the JZ ... After many years of coaching thousands of individuals on ... tracking app that does not require calorie counting or ...
(Date:10/20/2014)... Rockynol Retirement Community broke ground on ... $11 million project will include the latest in Assisted ... full-service restaurant style dining. , “We are excited to ... Living apartments,” said Kara Hanzie, Rockynol Executive Director during ... care and this investment is proof of our commitment.” ...
(Date:10/20/2014)... 20, 2014 Unveiled at the Sept. 18 ... Scorecard conservatively estimates member hospital ROI on membership dues at ... The Center provides $12.50 in value to member hospitals. The ... – Member Dues)/Member Dues. , “This is the first ... and we think the methodology is really sound,” said ...
(Date:10/19/2014)... Hastings and Hastings, a Phoenix personal ... throughout the greater Phoenix area and across Arizona reports ... to catastrophic automobile accidents. Statistics have indicated a steady ... Arizona. As such, Hastings and Hastings has seen a ... those who have been injured through no fault of ...
(Date:10/19/2014)... Having been working in the garment industry for decades, LunaDress’ ... to James, one of the company’s top designers, many ladies ... skirts that add beauty to them. Chiffon floor length outfits ... its new selection of 2014 long prom dresses. , ... are available in over 20 popular designs. The company intends ...
Breaking Medicine News(10 mins):Health News:JZ Fitness Nutrition App Launches on iTunes 2Health News:JZ Fitness Nutrition App Launches on iTunes 3Health News:Rockynol Retirement Community Expands Assisted Living Center 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 2Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 3Health News:2014 Long Prom Dresses From LunaDress Now Available In Over 20 Popular Designs 2
... IRVINE, Calif., Nov. 3 Endologix, Inc. (Nasdaq: ELGX ), ... John McDermott, President and Chief Executive Officer, is scheduled to present ... at the Canaccord Adams 3rd Annual Cardiovascular Conference at the Nikko ... Event: Canaccord Adams 3rd Annual Cardiovascular ...
... the same holds true for humans, researchers say , TUESDAY, Nov. ... sweet life may also be the short life. , New research ... 20 percent of their life span. , It,s unclear what ... impact of diets high in sugar, according to the study authors, ...
... is also a prescription for self-esteem among breast cancer ... Medicine research. Breast cancer survivors who lift weights regularly ... more satisfied with their intimate relationships compared with survivors ... study published in the journal Breast Cancer Research ...
... ... in Jackson, Miss. has started posting surgical videos as part of a new section ... surgery to correct sunken chest syndrome in pediatric patients. As part the new portion ... unique procedure by way of video. , ...
... 3 Triple-S Management Corporation (NYSE: GTS ), the ... revenues of $507.3 million and operating income of $15.4 million ... of $18.1 million, or $0.62 per diluted share, includes an ... share, in net realized and unrealized gains on investments and ...
... claims and risk management provider Avizent announced today the introduction ... medical experts are involved in workers, compensation claims from day ... the new service is to safely return injured employees to ... workers, comp claims. Avizent is one of only a few ...
Cached Medicine News:Health News:Endologix to Present at Three Upcoming Conferences 2Health News:Sugar Shortens Life Span in Worms 2Health News:Weight training boosts breast cancer survivors' body image and intimate relationship satisfaction 2Health News:New Video Post Shows Minimally Invasive Procedure To Correct Sunken Chest Syndrome 2Health News:Triple-S Management Corporation Reports Third Quarter 2009 Results 2Health News:Triple-S Management Corporation Reports Third Quarter 2009 Results 3Health News:Triple-S Management Corporation Reports Third Quarter 2009 Results 4Health News:Triple-S Management Corporation Reports Third Quarter 2009 Results 5Health News:Triple-S Management Corporation Reports Third Quarter 2009 Results 6Health News:Triple-S Management Corporation Reports Third Quarter 2009 Results 7Health News:Triple-S Management Corporation Reports Third Quarter 2009 Results 8Health News:Triple-S Management Corporation Reports Third Quarter 2009 Results 9Health News:Triple-S Management Corporation Reports Third Quarter 2009 Results 10Health News:Triple-S Management Corporation Reports Third Quarter 2009 Results 11Health News:Triple-S Management Corporation Reports Third Quarter 2009 Results 12Health News:Triple-S Management Corporation Reports Third Quarter 2009 Results 13Health News:Triple-S Management Corporation Reports Third Quarter 2009 Results 14Health News:Triple-S Management Corporation Reports Third Quarter 2009 Results 15Health News:Triple-S Management Corporation Reports Third Quarter 2009 Results 16Health News:Avizent's New TeamCOMP Approach Helps Ensure Lower Workers' Comp Costs and Faster Claims Resolution 2
(Date:10/20/2014)... VIEW, California , 20 de octubre de ... líder en el campo de la pulmonología intervencional, ... su Estudio RENEW, casi 3 meses antes de ... fundamental de exención de dispositivo de investigación (IDE) ... Medicamentos) para el sistema de espiral de reducción ...
(Date:10/20/2014)... Oct. 20, 2014 Valeritas, Inc., a leader ... patients with Type 2 diabetes, announced today that it ... Award. The award was presented October 16 th ... Columbus, Ohio . The Cardinal ... a variety of metrics specifically targeted at the importance ...
(Date:10/20/2014)... Oct. 20, 2014 Lpath, Inc. (NASDAQ: ... bioactive lipid-targeted therapeutics, received official notification from the European ... another key patent supporting its iSONEP™ and ASONEP™ ... European patent No. 2087002, claims compositions of matter ... two lead compounds, iSONEP and ASONEP. Sonepcizumab is ...
Breaking Medicine Technology:PneumRx concluye inscripción en prueba fundamental RENEW 2PneumRx concluye inscripción en prueba fundamental RENEW 3Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 2Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 3Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 2Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 3Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 4
... Company (Nasdaq: PRGO;TASE) today announced that Perrigo CFO Judy Brown ... 5, 2011 at 9:30 a.m. (IST) at the TASE Headquarters ... The day will include presentations on the Consumer Healthcare, ... and research and development. Perrigo Company is ...
... PARK, Calif., Oct. 4, 2011 CV Ingenuity, a ... a $16 million Series B round of financing led ... capital firm. Existing investors BioStar Ventures, Synergy Ventures and ... (CVI), which is focused on the development of a ...
Cached Medicine Technology:CV Ingenuity Announces Close of $16 Million Series B Financing Led by NEA 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: